← Leaderboards
Nicolas Collins
Vaccine Formulation Institute (Ch) Ltd
$6,937,118
Attributed
$6,937,118
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.5M · FY2023–25$5M$3.8M$2.5M$1.3M$0
'23
'24
'25
Funding mix
By agency
NIH$6,937,118 · 1
By mechanism
N01$6,937,118 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Vaccines”
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- Angee Greer · Ppd Development Lp$82,531,927
- Rhea Coler · Seattle Children'S Hospital$35,184,139
- Kevin Saunders · Duke University$18,106,404
- Daniel Hunter Reirden · Westat, Inc.$16,121,731
- Jason Dickens · Duke University$12,259,409
Research focus
VaccinesAccelerationAdjuvantAdvanced DevelopmentAntigensChromatographyClinical ResearchCommunitiesContractorCost EffectiveEfficacy StudyEvaluationFormulationGlobal HealthGood Manufacturing ProcessHamstersImmunogenicityImmunologic AdjuvantsInnovationLiposomesLiposome VectorMacaca MulattaManufactureNanoparticle
Grant awards (3)
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES$2,000,000
N01 · FY2025 · AI · contact PI
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES$3,488,070
N01 · FY2024 · AI · contact PI
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES$1,449,048
N01 · FY2023 · AI · contact PI